Literature DB >> 33086932

The bumpy road to achieve herd immunity in COVID-19.

Monica Neagu1,2.   

Abstract

Herd immunity is a form of indirect protection that is offered to the community when a large proportion of individuals contained in the community are immune to a certain infection. This immunity can be due to vaccination or to the recovery post-disease. Effective herd immunity in SARS-CoV-2 infection has several hurdles upon achievement. Herd immunity cannot be obtained concomitantly in many geographical areas because the areas have different population density and the societal measures to contain the spreading are different. A proportion of 50-66% of the population needs to be immunized naturally or artificially in this SARS-Cov2 pandemic and this percentage is not easily achievable. The duration of herd immunity is another issue while information on the long-term immune response against SARS-CoV2 is yet scarce. Epitope stability, another issue to be solved when achieving herd immunity, is important. Mutation in the viral structure will call upon other sets of neutralizing antibodies and hence for other herd immunity type installment. The societal tactics to achieve the much-needed herd immunity should be developed keeping in mind the welfare of the population. Without being exhaustive, throughout our paper we will elaborate on each of the hurdles encountered in developing herd immunity to SARS-Cov2 infection.

Entities:  

Keywords:  COVID-19; herd immunity; immune memory

Year:  2020        PMID: 33086932     DOI: 10.1080/15321819.2020.1833919

Source DB:  PubMed          Journal:  J Immunoassay Immunochem        ISSN: 1532-1819


  11 in total

1.  How will emerging SARS-CoV-2 variants impact herd immunity?

Authors:  Giuseppe Lippi; Brandon M Henry
Journal:  Ann Transl Med       Date:  2021-04

2.  Seroprevalence of anti-SARS-CoV-2 IgG antibodies: relationship with COVID-19 diagnosis, symptoms, smoking, and method of transmission.

Authors:  Kora-Mareen Bühler; Victor Echeverry-Alzate; Javier Calleja-Conde; Pedro Durán-González; Lucia Segovia-Rodriguez; Jose A Morales-García; Mateo Pérez-Wiesner; David Cables-Chozas; Fernando Rodríguez de Fonseca; Alberto Delgado-Iribarren; Paloma Merino-Amador; Fernando González-Romo; Elena Giné; Jose Antonio López-Moreno
Journal:  IJID Reg       Date:  2022-05-27

3.  Attitudes, acceptance and hesitancy among the general population worldwide to receive the COVID-19 vaccines and their contributing factors: A systematic review.

Authors:  Fidelia Cascini; Ana Pantovic; Yazan Al-Ajlouni; Giovanna Failla; Walter Ricciardi
Journal:  EClinicalMedicine       Date:  2021-09-02

4.  COVID-19 vaccine hesitancy and acceptance in Mexico: a web-based nationwide survey.

Authors:  Diego Ramonfaur; David Eugenio Hinojosa-González; Gloria Paulina Rodriguez-Gomez; David Alejandro Iruegas-Nuñez; Eduardo Flores-Villalba
Journal:  Rev Panam Salud Publica       Date:  2021-10-18

Review 5.  Performance Evaluation of Lateral Flow Assays for Coronavirus Disease-19 Serology.

Authors:  Lucy Ochola; Paul Ogongo; Samuel Mungai; Jesse Gitaka; Sara Suliman
Journal:  Clin Lab Med       Date:  2021-11-03       Impact factor: 1.935

6.  Influence of heterogeneous age-group contact patterns on critical vaccination rates for herd immunity to SARS-CoV-2.

Authors:  Joan Saldaña; Caterina Scoglio
Journal:  Sci Rep       Date:  2022-02-16       Impact factor: 4.379

Review 7.  Rifampicin for COVID-19.

Authors:  George D Panayiotakopoulos; Dimitrios T Papadimitriou
Journal:  World J Virol       Date:  2022-03-25

8.  Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers.

Authors:  Sabina Zurac; Cristian Vladan; Octavian Dinca; Carolina Constantin; Monica Neagu
Journal:  Sci Rep       Date:  2022-07-26       Impact factor: 4.996

9.  COVID‑19 vaccination and IgG and IgA antibody dynamics in healthcare workers.

Authors:  Sabina Zurac; Luciana Nichita; Bogdan Mateescu; Cristian Mogodici; Alexandra Bastian; Cristiana Popp; Mirela Cioplea; Claudiu Socoliu; Carolina Constantin; Monica Neagu
Journal:  Mol Med Rep       Date:  2021-06-16       Impact factor: 2.952

Review 10.  Testing Antigens, Antibodies, and Immune Cells in COVID-19 as a Public Health Topic-Experience and Outlines.

Authors:  Monica Neagu; Carolina Constantin; Mihaela Surcel
Journal:  Int J Environ Res Public Health       Date:  2021-12-14       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.